Revenue during the quarter surged 65.93 percent to $7.69 million from $4.64 million in the previous year period.

Operating loss for the quarter was $21.37 million, compared with an operating loss of $15.42 million in the previous year period.

"2016 was a transformative year for Blueprint Medicines in which we achieved all of our corporate goals, including a number of important milestones," said Jeff Albers, chief executive officer of Blueprint Medicines. "When Blueprint Medicines began operations in 2011, we were committed to building a diversified portfolio, grounded in our differentiated scientific platform, with the potential to bring innovative targeted therapies to patients in areas of high medical need. In 2016 we began to realize this vision, and 2017 will be a year where that vision comes into clearer focus. In 2016, we announced proof-of-concept data from three Phase 1 trials in genomically-defined patient populations, received FDA approval to begin a Phase 1 trial for BLU-667, continued to expand our pipeline and announced a collaboration with Roche that enables us to accelerate and build upon our efforts in cancer immunotherapy. Looking ahead to 2017, we expect multiple potential milestones, including presenting updated data for our ongoing Phase 1 trials for BLU-285 and BLU-554, which will provide further insight into the safety, clinical activity and clinical development pathways for these investigational medicines."